Skip to main content
. Author manuscript; available in PMC: 2017 Feb 8.
Published in final edited form as: Nat Med. 2016 Aug 8;22(9):1056–1061. doi: 10.1038/nm.4155

Figure 3. Knockdown of STAG2 or STAG3 impairs the effects of vemurafenib on inhibiting melanoma xenograft tumor growth in vivo.

Figure 3

(a) Nude mice bearing xenograft tumors of A375 cells stably expressing pTRIPZ-shSTAG2#60 were treated with vehicle, doxycyline (Dox), vemurafenib (Vem), or both doxycyline and vemurafenib. Unpaired two-tailed Student's t-test was performed to compare between two groups of mice that were treated with vemurafenib (mean ± s.e.m. * P < 0.05). The data variance is similar between groups. n = 5–7. (b) Waterfall plots showing the percent change in tumor volume at day 7 for the individual tumors in each treatment group of the STAG2 knockdown experiment. (c) Representative images of mouse tumor samples from the STAG2 knockdown experiment subjected for various immunohistochemical analyses as indicated. Scale bar: 50 μm. (d) Nude mice bearing xenograft tumors of A375 cells stably expressing pLKO-shSTAG3#69 were treated with control or vemurafenib (Vem) diet. Unpaired two-tailed Student's t-test was performed to compare between two groups of mice that were treated with vemurafenib (mean ± s.e.m. * P < 0.05). The data variance is similar between groups. n = 5–7. (e) Waterfall plots showing the percent change in tumor volume at day 8 for the individual tumors in each treatment group of the STAG3 knockdown experiment. (f) Representative images of mouse tumor samples from the STAG3 knockdown experiment subjected for various immunohistochemical analyses as indicated. Scale bar: 50 μm.